Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Generation of dual specific bivalent BiTEs (dbBIspecific T-cell engaging antibodies) for cellular immunotherapy ; volume:19 ; number:1 ; day:5 ; month:9 ; year:2019 ; pages:1-14 ; date:12.2019
BMC cancer ; 19, Heft 1 (5.9.2019), 1-14, 12.2019
- Urheber
-
Kujawski, Maciej
Li, Lin
Bhattacharya, Supriyo
Wong, Patty
Lee, Wen-Hui
Williams, Lindsay
Li, Harry
Chea, Junie
Poku, Kofi
Bowles, Nicole
Vaidehi, Nagarajan
Yazaki, Paul
Shively, John E.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-019-6056-8
- URN
-
urn:nbn:de:101:1-2020012220135192957965
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:59 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Kujawski, Maciej
- Li, Lin
- Bhattacharya, Supriyo
- Wong, Patty
- Lee, Wen-Hui
- Williams, Lindsay
- Li, Harry
- Chea, Junie
- Poku, Kofi
- Bowles, Nicole
- Vaidehi, Nagarajan
- Yazaki, Paul
- Shively, John E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Love Bites
Soul bites
Magic bites
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Love Bites
Soul bites
Magic bites
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
Molecular insights into recognition of GUCY2C by T-cell engaging bispecific antibody anti-GUCY2CxCD3
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD33/CD3-bispecific T-cell engaging (BiTE®) antibody construct targets monocytic AML myeloid-derived suppressor cells
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Evaluation of Bispecific T-Cell Engagers Targeting Murine Cytomegalovirus
Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
Targeted Phagocytosis Induction for Cancer Immunotherapy via Bispecific MerTK-Engaging Antibodies
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Love Bites
Soul bites